We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Self-Taught AI Tool Diagnoses and Predicts Severity of Common Lung Cancer

By LabMedica International staff writers
Posted on 12 Jun 2024
Print article
Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)
Image: Three of 46 histomorphological phenotype clusters in small block tiles identified by AI from images of cancerous lung tissue (Photo courtesy of Dr. N. Coudray/NYU Grossman School of Medicine)

A computer program powered by artificial intelligence (AI) and trained on nearly half a million tissue images can effectively diagnose cases of adenocarcinoma, the most prevalent type of lung cancer.

The computer program developed and tested by researchers at NYU Langone Health (New York, NY, USA) and the University of Glasgow (Glasgow, UK) provides an unbiased, detailed, and reliable second opinion for patients and oncologists regarding the presence of the cancer and the possibility and timing of its return, also known as its prognosis. This is because the program incorporates structural features of tumors from 452 adenocarcinoma patients, who are among the more than 11,000 patients in the U.S. National Cancer Institute’s Cancer Genome Atlas. Importantly, the program operates independently and is "self-taught," deciding by itself which structural features are most critical for assessing the severity of the disease and its impact on tumor recurrence.

In their research, the algorithm, known as histomorphological phenotype learning (HPL), successfully differentiated between adenocarcinoma and similar types of lung cancer, such as squamous cell cancers, with 99% accuracy. The HPL program also demonstrated a 72% accuracy rate in predicting the likelihood and timing of cancer recurrence after treatment, surpassing the 64% accuracy achieved by pathologists who analyzed the same tumor images manually. The research team envisions that, with continued advances in understanding lung cancer biology, pathologists will increasingly review tissue samples on their computer rather than through traditional microscopy and will employ their AI program to further analyze and visualize these scans.

The researchers aim to use the HPL algorithm to assign each patient a score from 0 to 1 that reflects their statistical probability of survival and tumor recurrence for up to five years. They emphasize that the self-learning nature of HPL means the program's accuracy will improve as it processes more data over time. The team is now looking to develop similar AI-based programs for other types of cancer, such as breast, ovarian, and colorectal cancers, which will also incorporate key morphological and molecular data. Plans are also underway to enhance the precision of the adenocarcinoma HPL program by integrating additional data from hospital electronic health records, including information on other illnesses, diseases, income levels, and residential zip codes.

“Our new histomorphological phenotype learning program has the potential to offer cancer specialists and their patients a quick and unbiased diagnostic tool for lung adenocarcinoma that, once further testing is complete, can also be used to help validate and even guide their treatment decisions,” said study lead investigator Nicolas Coudray, PhD, a bioinformatics programmer at NYU Grossman School of Medicine and Perlmutter Cancer Center. “Patients, physicians, and researchers know they can rely on this predictive modeling because it is self-taught, provides explainable decisions, and is based only on the knowledge drawn specifically from each patient’s tissue, including such features as its proportion of dying cells and tumor-fighting immune cells and how densely packed the tumor cells are.” The study was published in Nature Communications on June 11, 2024.

Related Links:
NYU Langone Health
University of Glasgow

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.